Quotes delayed, except where indicated otherwise. Currency in GBp.
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.
On track to meet revenue guidance for the enlarged Group of £37-£41 million for FY2017, with strong H2 order book …
Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research Access to CRISPR for the …
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the international life sciencetools business today announces a trading update …
Cambridge, UK, 25 November 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and …
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth Expansion of …
License programme with milestone payments of up to £50 million plus royalties on product sales Horizon to in-license novel kinase …
|Operating Profit / (Loss)||(5,350)||(10,290)|
|Profit / (Loss) before tax||(6,073)||(10,540)|
|Cash & cash equivalents||18,215||25,067|
“The new science of personalised medicine” (PWC report 2011).
Currently, the total US market for personalised medicine and healthcare (wide, by definition) is estimated at £149bn and is projected to surpass £288bn by 2015
The core diagnostic and therapeutic segment (pharmaceuticals, medical device and diagnostic companies) is estimated at £15bn, with an estimated annual growth rate of c.10%, to reach £27bn by 2015.
30% of all pharma companies now require research & development compounds to have a patient-relevant biomarker
Investor’s Chronicle (17 Apr 2015)
“Final Results out this week revealed that the Co had outperformed expectations, with full year revenues rising to £11.9m, 8% ahead of consensus estimates. BUY”
Mail on Sunday (23 Mar 2015)
“Discover the life science firm that will broaden your horizons.”
Shares (Dec 2014)
“15 for 2015: Horizon Discovery”
Panmure Gordon (House Broker)
“Horizon offers investors a rare opportunity to gain exposure to an enabling healthcare company operating a unique and enabling technology platform within its chosen markets.”